Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest. 2021 03; 159(3):1283-1287.

View in: PubMed

subject areas

Age Factors
Aged
Area Under Curve
Diagnosis, Differential
Female
Follow-Up Studies
Humans
Lung
Lung Neoplasms
Male
Multiple Pulmonary Nodules
Neoplasms
Proteomics
Risk Factors
Smoking
Solitary Pulmonary Nodule
Tomography, X-Ray Computed
Tumor Burden

authors with profiles

Gerard A. Silvestri
Nichole Tripician Tanner